MAPT and Alzheimer disease: In regard to APOE4+ vs. APOE4− AD patients, tau pathology also appears to differ according to APOE genotype, although the primary differences here appear to revolve around the regional pattern of NFT distribution, as opposed to the overall levels (Table 5).